Provided herein are methods, compositions, kits, and systems for diagnosing, predicting, and treating gastric cancer for a subject based on the presence and level of antibodies against particular H. pylori proteins in a biological sample obtained from the subject. In particular, provided herein are methods for identifying a subject having increased risk of developing gastric cancer, methods for detecting gastric cancer in a subject, methods for determining an H. pylori antibody signature comprising antibodies, contained in a biological sample from a subject, that specifically bind to immobilized H. pylori antigens, and kits comprising components and instructions for performing the methods of this disclosure.

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

The present invention relates to inhibitors of the interaction between H. pylori IIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

The present invention provides a method for blocking immunosuppressive functions of pathogens, comprising: applying to an environment where the pathogens exist a composition that blocks immunosuppressive functions of the pathogens. The immunosuppressive functions are provided by an immunosuppressive substance secreted or produced by the pathogens. The composition includes a function inhibitor that comprises an antibody identifying the immunosuppressive substance or a fragment thereof. Use of the function inhibitor composition is also disclosed.

The present invention relates to a monoclonal antibody that inhibits immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody. The monoclonal antibody or antigen-binding fragment thereof bind to a peptide consisting an amino acid sequence represented by MEKVGKDGVITVE (SEQ ID NO: 1). The present invention also discloses use of the invented monoclonal antibody or antigen-binding fragment thereof, and method of preparation for such hybridomas.

The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ.ID.No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ.ID.No.1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ.ID.No.1, and
whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

The present invention can be included in the field of diagnostics. The present invention provides hybridomas, antibodies and test devices for the detection of bacteria of the genus Campylobacterin a sample. Further, the present invention discloses the uses of the antibodies and a method for detecting bacteria of the genus Campylobacter. The antibodies of the present invention are specific for DNA-Binding Protein from Starved Cells (Dps) and provide less false positives and a higher sensitivity when used in an immunochromatographic test device than other antibodies used to detect bacteria of the genus Campylobacter.

An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies. The preparation is prepared from human plasma, has specific complement activating activity, and, in an in vitro assay with human serum suitable to determine the ability of the antibody preparation to activate complement unspecifically, the antibody preparation generates substantially no C5a and/or substantially no C3a. The antibody preparation can have medical uses.

The present disclosure provides non-parenteral compositions comprising a recombinant Spirulina comprising at least one exogenous therapeutic. Compositions of the present disclosure can be used as vaccines and/or therapeutic drugs. The present disclosure also provides methods of making recombinant Spirulina comprising at least one exogenous therapeutic, and methods of treatment.